Israel · Delayed Price · Currency is ILS · Price in ILA Evogene Earnings Call Transcripts
Fiscal Year 2025
-
Strategic refocus on ChemPass AI and core markets led to lower expenses and improved net loss for 2025, despite revenue declines. Cash position is strong, with anticipated inflows from asset sales and partnerships expected to drive future growth.
-
Q3 2025 saw a strategic shift to AI-driven small molecule design, major cost reductions, and a $7.9M gain from asset sales. Operating loss and expenses dropped sharply, with new pharma and ag-chem collaborations expected in 2026.
-
Revenue rose to $3.2M in H1 2025, driven by Casterra seed sales, while operating loss narrowed due to major cost reductions. Strategic focus shifted to ChemPass AI, with asset sales and equity raise providing 18 months of runway. Key partnerships and new AI capabilities were announced.
-
Q1 2025 saw revenues drop to $2.4M due to prior year one-time license fees, but Casterra seed sales grew and major cost reductions improved net loss to $3M. The Lavie Bio asset sale to ICL is set to strengthen the balance sheet, with cash runway expected through 2026.
Fiscal Year 2024
-
2024 saw revenue rise 52% to $8.5M and net loss narrow to $18.1M, driven by higher seed sales and collaborations. Expense reductions and a focus on AI-powered drug discovery and subsidiary exits are set to further improve financials in 2025.
-
Revenues for the first nine months of 2024 rose to $6.9 million, with Casterra and Lavie Bio driving growth, though Q3 revenues declined year-over-year due to a prior one-time license fee. Cash position remains strong after a $5.5 million fundraising, and the company anticipates continued revenue growth, especially from Casterra and Lavie Bio's Yalos expansion.
-
Revenues rose sharply year-over-year, with net loss narrowing due to higher sales and lower expenses. Casterra, Lavie Bio, and Biomica achieved key milestones, and strong cash reserves are projected by year-end, supported by robust order fulfillment and new partnerships.